• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

    9/22/25 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email

    NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from its Phase 1/2 clinical study of CRB-701 (SYS6002). Data from over 100 participants with either head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors will be presented.

    The KOL event will be held at the Berlin Germany Marriott starting at 10AM CEST on Sunday October 19th. The event will feature insights from leading HNSCC experts:

    • Ari Rosenberg, MD – University of Chicago
    • Glenn Hanna, MD - Dana-Farber Cancer Institute
    • Cesar Augusto Perez Batista, MD - Sarah Cannon Research Institute

    A live question and answer session will follow the formal presentation. To register for either virtual or in-person attendance, click here.

    The Phase 1/2 dose optimization data will be presented as a poster at ESMO 2025, starting at noon CEST on October 19, 2025.

    The ongoing clinical trial (NCT06265727), being conducted in the U.S. and Europe, is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high Nectin-4 expression. The study enrolled primarily HNSCC and cervical patients.

    About Ari Rosenberg, MD

    Ari Rosenberg, MD, is a medical oncologist and Associate Professor of Medicine at the University of Chicago who specializes in using basic, translation and clinical research to improve the lives of his patients. As a clinical investigator, Dr. Rosenberg focuses on developing novel therapeutic strategies, including immunotherapy, for patients with head and neck cancer and thyroid cancer. He is also establishing methods to reduce treatment-related toxicity for better outcomes and quality of life. In 2025, Dr. Rosenberg was named to the prestigious list of 40 Under 40 in Cancer, an award that recognizes him as one of the nation's most promising young oncology professionals and celebrates his contributions to improve the lives of those affected by cancer.

    About Glenn Hanna, MD

    Glenn Hanna, MD, completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute (DFCI) in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He joined the faculty of the Center for Head and Neck Oncology in 2017. Dr. Hanna is the Director of the Center for Cancer Therapeutic Innovation (CCTI), the early drug development program at DFCI. His clinical and translational research efforts focus on precision medicine approaches to treat head and neck cancers. He has special interests in salivary gland cancers and rare head and neck malignancies, and in molecular and immunologic biomarker discovery.

    About Cesar Augusto Perez Batista, MD

    Cesar Augusto Perez Batista, MD, is Director of the Drug Development Unit at Sarah Cannon Research Institute at Florida Cancer Specialists in Lake Nona, Florida. A recognized cancer expert, he leads early-phase trials for solid tumors with a focus on head and neck cancer and serves as Executive Chair of the Head and Neck Cancer Research Group for the Sarah Cannon Network. He has served on several American Society of Clinical Oncology (ASCO) head and neck committees and is an ASCO Ambassador. Dr. Perez is an Affiliate Associate Professor at the University of Central Florida and previously co-led Phase 1 and head and neck oncology research at the University of Miami, following earlier faculty work at the University of Louisville, where he twice earned the Best Faculty Teacher Award. He trained at the Cleveland Clinic and the University of Miami, where he was Chief Fellow and received the Peter A. Cassileth, MD Award. He is board certified in medical oncology, hematology, and internal medicine.

    About CRB-701

    CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using monomethyl auristatin E as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

    INVESTOR CONTACT:

    Sean Moran

    Chief Financial Officer

    Corbus Pharmaceuticals

    [email protected]

    Dan Ferry

    Managing Director

    LifeSci Advisors, LLC

    [email protected]



    Primary Logo

    Get the next $CRBP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    7/30/2025$28.00Buy
    B. Riley Securities
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRBP
    SEC Filings

    View All

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    9/16/25 8:45:28 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

    10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    8/5/25 4:30:40 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    8/5/25 9:00:29 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Altmeyer Anne sold $10,096 worth of shares (1,392 units at $7.25) and was granted 4,800 shares, increasing direct ownership by 122% to 6,191 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    6/2/25 4:30:13 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins John Kenneth sold $20,465 worth of shares (2,783 units at $7.35) and was granted 4,800 shares, increasing direct ownership by 72% to 4,833 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    6/2/25 4:30:16 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kung Winston was granted 4,800 shares, increasing direct ownership by 86% to 10,366 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    6/2/25 4:30:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

    NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from its Phase 1/2 clinical study of CRB-701 (SYS6002). Data from over 100 participants with either head and neck squamous cell carcinoma (HNSCC), cervical, or metastatic urothelial tumors will be presented. The KOL event will be held at the Berlin Germany Marriott starting at 10AM CEST on Sunday October 19th. The event will feature ins

    9/22/25 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

    Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. A Fast Track designation for relapsed or refractory metastatic cervical cancer was granted

    9/16/25 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025 NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended June 30, 2025. "The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs," said Y

    8/5/25 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    9/24/24 4:04:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/11/24 5:34:06 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/6/24 4:00:46 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

    NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

    8/20/24 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

    NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

    2/28/24 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 4:05:29 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care